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Introduction 
The xenotransplantation of pig organs and tissues aimed at 
overcoming the world-wide shortage that exists for these in humans will 
require multiple genetic modifications to be incorporated to overcome 
rejection and associated problems. We have recently produced α1,3 
galactosyltransferase knockout (GTKO)  pigs expressing human (h) 
CD55&59, fucosyltransferase (HTF), hCD39 and hTBM This was done 
by breeding GTKO pigs to animals expressing human hCD55 and 
hCD59 plus HTF and then transfecting adult fibroblasts obtained from 
their progeny  with a hCD39 plus hTBM construct.  Transfected cells 
were then selected based on hCD39 expression and used for animal 
cloning to produce these (Figure 1). The generation of these animals 
represents almost two decades of research focussed on developing the 
necessary molecular, cellular and reproductive technologies. Having 
produced GT KO pigs expressing five transgenes, it is an appropriate 
juncture to reflect on how this was achieved and what progress still 
needs to be made in terms of transgenesis technology to advance 
xenotransplantation to the clinic.
In the Beginning 
The production of transgenic pigs was originally restricted to using 
pronuclear microinjection which was beyond the reach of many groups 
because of the relatively high cost of doing this. Having developed a 
large scale technology platform for producing growth hormone 
transgenic pigs in the early 1990’s we used this to produce transgenic 
pigs for xenotransplantation research [1]. Initial studies focussed on 
the expression of multiple human complement regulatory factors to 
overcome hyper acute rejection. However, we realised that we needed a 
new approach to produce pigs expressing multiple transgenes, because 
cross-breeding animals containing a single modification took too long. 
As a result   we demonstrated that it was possible to produce   animals 
containing CD55, CD59 and H-transferase by co-injecting these three 
constructs at the same time [2].
Cloning and GTKO Pigs
While we were one of the first groups to knock out Gal the major 
xeno antigen, in mice using gene targeting in embryonic stem cells 
(ESCs) [3]. The lack of pig embryonic at the time meant that we and 
others   were unable to do this in pigs. The advent of animal cloning with 
the birth of Dolly [2] changed this however as ESCs were longer needed 
to perform a knockout.  Subsequently we and several others produced 
cloned pigs [4,5] and then GTKO pigs [6] within a decade of Dolly. 
This was a remarkable achievement given the number of technologies 
that had to be developed, from in vitro oocyte maturation [7] to the 
use of promoter-less constructs to increase targeting efficiencies to 
workable levels [8] for this to happen.  Previously we had reported that 
GTKO mice developed cataracts and there was concern that GTKO 
pigs would also. However by outbreeding our original Gal founder 
females to males of different breeds and then crossing GTKO animals 
we showed that GTKO  pigs were  viable and produced normal sized 
litters and. We also demonstrated that GTKO   pigs could be produced 
by cloning using GTKO fetal fibroblasts [9].
The production of GTKO pigs using   gene targeting of somatic cells 
and cloning heralded a new approach to the production of transgenic 
pigs.  By transfecting somatic cells and then selecting those cells which 
expressed the transgene two of the major limitations associated with 
pronuclear injection could be overcome namely, the production of 
animals  which did not contain the transgene (typically 80-90%) as 
well as those  that did but did not express it (normally around 50%) 
could be overcome. In parallel, advances in in vitro embryo production 
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Figure 1:  Production of GTKO pigs expressing human complement regulatory 
factors CD55 and CD59, fucosyltransferase (HTF), human CD39 (CD39) and 
human thrombomodulin (TBM).
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meant that we could use oocytes from slaughterhouse ovaries rather 
than collect one cell embryos from tens of live animals for pronuclear 
microinjection, further reducing costs and improving efficiencies. For 
example, we were able to produce 15 CD39 pigs for experimental and 
breeding purposes from eight transfers, whereas using pronuclear 
microinjection would have required up to three times this number of 
transfer to account for its inherent inefficiencies.
Despite these advances the major limitation to producing animals 
expressing multiple transgenes remained, namely the need to breed 
animals together to produce animals expressing multiple transgenes. 
While we had used co-injection in the past we had long recognised that 
the best approach would be one where multiple transgenes could be 
incorporated into the GTKO targeting construct so that they could be 
inserted as single copies at the same time as knocking out GT [10]. 
This approach would also allow all modifications to be inherited as a 
single unit, eliminating the production of those animals that did not 
contain all the modifications as a result of segregation during meiosis. 
To overcome this problem we have used the 2A ribosome sequence to 
produce transgenic mice expressing three genes on the one construct 
[11]. We then used this sequence to produce a construct consisting of 
CD39 and hTBM. This was then transfected onto our existing GTKO 
CD55+59 plus h transferase background and cells screened for CD39 
expression. Suitably expressing cells were then used to produce GTKO 
pigs expressing all five transgenes ad described above  
Stem Cells, Meganucleases and Beyond  
In reviewing the literature in 2011 we suggested that for 
xenotransplantation to advance to the clinic, a cell type which could 
last longer in culture than fibroblasts was needed to produce pigs 
containing multiple modifications [10]. As such much of our research 
in recent years   has focussed on isolating embryonic stem cells [10]. 
These together with other cell types such as induced pluripotent stem 
cells survive longer in culture allowing multiple modifications to 
be made and examined before using    these for animal cloning. The 
ability to target specific sites in the genome using zinc finger nucleases 
has provided an alternative approach to knocking out GT using 
homologous recombination [12]. The use of Transcription activator-
like effector nucleases (TALENS) also allows DNA to be inserted at 
the same time as knocking out gene function [13] and may provide 
an alternative approach to producing GTKO pigs expressing multiple 
transgenes inserted as single copies at this site.
This is  a rapidly advancing  field and it is   now possible to envisage 
a technology platform in the near  future where stem cells or similar 
are transfected in  vitro using one of these approaches,  screened to 
confirm integration and expression  and then used for  cloning to 
produce animals  expressing multiple transgenes inserted at the GT 
locus. Furthermore  the use   CRISPR/Cas9  is   allowing  changes 
to be made by microinjecting directly into the cytoplasm of zygotes 
at similar if not higher rates  than that achieved with cloning  [14] 
and the production  of GTKO pigs has already reported using  this 
method in cells [15]. Whatever approach is ultimately used, we are 
already witnessing a wave of targeted modifications in pigs as a result 
of these technologies which has changed the way we make transgenic 
pigs. However the challenge for xenotransplantation is not only to be 
able to knockout both GT alleles but at the same time insert multiple 
transgenes at each allele.  Something which is yet to be achieved despite 
more than two decades of research. 
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